Yunlong Lu
Overview
Explore the profile of Yunlong Lu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
485
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang L, Ma X, Zhou L, Luo M, Lu Y, Wang Y, et al.
J Med Chem
. 2025 Feb;
68(5):5275-5291.
PMID: 39968846
Gefitinib exhibits significant clinical efficacy in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) sensitive mutations. However, its efficacy is severely limited by acquired resistance....
2.
Peng M, Jaeger K, Lu Y, Fan Z, Zeng W, Sampathkumar A, et al.
Mol Plant
. 2025 Jan;
18(3):457-467.
PMID: 39789846
Plants are able to sense and remember heat stress. An initial priming heat stress enables plants to acclimate so that they are able to survive a subsequent higher temperature. The...
3.
Zheng T, Wang S, Liu W, Lu Y
J Med Chem
. 2025 Jan;
68(2):1002-1020.
PMID: 39761381
The lysine acetyltransferase 6A (KAT6A, MOZ, MYST3) is a member of the MYST family of protein acetyltransferases, which are essential for different biological processes such as craniofacial, embryonic, stem cell...
4.
Lu Y, Zhao Z, Wang S, Zheng T, Chen X, Liu L, et al.
Eur J Med Chem
. 2024 Oct;
279:116897.
PMID: 39353239
Elacestrant, the first oral selective estrogen receptor degrader (SERD), has been approved for ER positive breast cancer in 2023. Recent study showed that elacestrant has moderate pharmacokinetic property and the...
5.
Lu Y, Liang Z, Liu L, Zhou Y, Liu C, Zhao Z, et al.
Eur J Med Chem
. 2024 Jun;
275:116534.
PMID: 38870830
Combination therapy proven to be an effective therapeutic approach for estrogen receptor (ER)-positive breast cancer. Currently, cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are combined with aromatase inhibitors (AIs) or selective estrogen...
6.
Xie Z, Liu C, Yu H, Xie Z, Sun C, Zhu Y, et al.
Orphanet J Rare Dis
. 2024 Mar;
19(1):123.
PMID: 38486238
Background: Pathogenic missense variants in the dystrophin (DMD) gene are rarely reported in dystrophinopathies. Most DMD missense variants are of uncertain significance and their pathogenicity interpretation remains complicated. We aimed...
7.
Zhou L, Lu Y, Liu W, Wang S, Wang L, Zheng P, et al.
Exp Hematol Oncol
. 2024 Mar;
13(1):26.
PMID: 38429828
A drug conjugate consists of a cytotoxic drug bound via a linker to a targeted ligand, allowing the targeted delivery of the drug to one or more tumor sites. This...
8.
Li F, Wen Z, Wu C, Yang Z, Wang Z, Diao W, et al.
J Med Chem
. 2024 Jan;
67(3):1982-2003.
PMID: 38261008
Induction of immunogenic cell death (ICD) and activation of the cyclic GMP-AMP synthase stimulator of interferon gene (cGAS-STING) pathway are two potent anticancer immunotherapeutic strategies in hepatocellular carcinoma (HCC). Herein,...
9.
Zhang B, Han J, Zhou D, Jiang J, Zhong J, Lu Y, et al.
J Comp Eff Res
. 2024 Jan;
13(2):e230035.
PMID: 38205729
To evaluate the costs and consequences of two front-line atrial fibrillation (AF) treatments from Chinese healthcare system perspective: radiofrequency catheter ablation (RFCA) using ThermoCool SmartTouch Catheter guided by Ablation Index...
10.
Xie Z, Lu Y, Liu C, Sun C, Yu J, Ling C, et al.
J Clin Lab Anal
. 2023 Nov;
37(21-22):e24987.
PMID: 37968799
Background: An accurate genetic diagnosis of Becker muscular dystrophy (BMD) can be sometimes challenging due to deep intronic DMD variants. Here, we report on the genetic diagnosis of a BMD...